Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis
Kavita Radhakrishnan, Adrian M. Di Bisceglie, K. Rajender Reddy, Joseph K. Lim, Josh Levitsky, Mohamed A. Hassan, Jama M. Darling, Jordan J. Feld, Lucy Akushevich, Monika Vainorius, David R. Nelson, Michael W. Fried, Robert S. Brown, Norah A. Terrault – 7 August 2019 – Recent studies have suggested a negative impact of hepatocellular carcinoma (HCC) on sustained virologic response (SVR) to hepatitis C virus (HCV) direct acting antivirals (DAAs).